Skip to main content

Table 1 Basic characteristics of patients receiving OAT in 2014 and 2017 in Sweden and Norway

From: Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

 

2014

2017

Country

Sweden

Norway

Sweden

Norway

OAT studypopulation, n

2663

6057

2739

5545

Gender, n (%)

 Male

1911 (72)

4266 (70)

1961 (72)

3870 (70)

 Female

752 (28)

1791 (30)

778 (28)

1675 (30)

Age, n (%)

 18–35

671 (25)

1219 (20)

647 (24)

878 (16)

 36–45

817 (31)

2181 (36)

819 (30)

1747 (32)

 46–55

744 (28)

2044 (34)

713 (26)

1998 (36)

 56–75

431 (16)

613 (10)

560 (20)

922 (17)

Mean age (SD)

 Male

44 (10)

44.1 (9)

45.1 (11)

46.1 (9)

 Female

43.5 (11)

43.1 (9)

44.3 (12)

45.2 (10)

OAT medication, n (%)a

 Methadone/levomethadone

1267 (48)

2810 (46)

1198 (44)

2504 (45)

 Buprenorphine

875 (33)

2049 (34)

1075 (39)

2190 (40)

 Buprenorphine/naloxone

521 (20)

1198 (20)

466 (17)

851 (15)

  1. Sources: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD)
  2. OAT Opioid agonist therapy, SD Standard deviation
  3. aLast registered OAT medication each calendar year